The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

31 Jul 2017 07:00

RNS Number : 5054M
Silence Therapeutics PLC
31 July 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Silence Therapeutics Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Richard Griffiths and controlled undertakings

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

27 July 2017

6. Date on which issuer notified:

28 July 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

 > 25,26

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00B9GTXM62

17,458,481

17,458,481

18,838,695

18,838,695

26.92%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

18,838,695

26.92%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Blake Holdings Limited

7,550,731

Seren Investment Management Limited

8,223,507

Oak Trust Limited

182,837

Richard Griffiths - indirect holdings

692,153

Sarossa Plc

2,189,467

Total

18,838,695

 

 

The above undertakings are all controlled by Richard Griffiths

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

James Sutcliffe

15. Contact telephone number:

+ 44 1534 719 761

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLURSVRBRABOAR
Date   Source Headline
16th Jan 20132:16 pmRNSHolding(s) in Company
14th Jan 20133:08 pmRNSReplacement - Exercise of warrants
14th Jan 20137:00 amRNSExercise of warrants
2nd Jan 20138:36 amRNSAppointment of Chief Medical Officer
31st Dec 201210:30 amRNSHolding(s) in Company
28th Dec 20127:00 amRNSTotal Voting Rights
6th Dec 20124:22 pmRNSHolding(s) in Company
3rd Dec 20123:12 pmRNSOption exercise
3rd Dec 20121:36 pmRNSHolding(s) in Company
3rd Dec 20121:34 pmRNSHolding(s) in Company
30th Nov 201212:52 pmRNSHolding(s) in Company
30th Nov 20128:05 amRNSHolding(s) in Company
30th Nov 20127:00 amRNSOption Exercise and TVR
28th Nov 20128:33 amRNSDirector/PDMR Shareholding
28th Nov 20127:49 amRNSSubscription and Conversion
21st Nov 20127:00 amRNSProposed Placing
5th Nov 201212:52 pmRNSAdviser Change of Name
5th Nov 201210:24 amPRNUS allows two key patents for Silence Therapeutics
19th Oct 20127:00 amPRNExercise of warrants
15th Oct 20127:01 amPRNExercise of warrants
15th Oct 20127:00 amPRNAppointment of finance director
25th Sep 20127:00 amPRNInterim Results for the Six Months Ended 30 June 2012
20th Sep 20122:59 pmPRNNotice of Results
18th Sep 20127:00 amPRNAppointment of Chief Medical Adviser
10th Sep 201211:12 amPRNTR-1: Notification of Major Interest in Shares
10th Sep 20127:00 amPRNSignificant Pre-clinical Data in Acute Lung Injury
4th Sep 201212:19 pmPRNTR-1: Notification of Major Interest in Shares
29th Aug 20124:40 pmRNSSecond Price Monitoring Extn
29th Aug 20124:35 pmRNSPrice Monitoring Extension
24th Aug 20122:41 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
22nd Aug 20127:00 amPRNCollaboration with MiReven Pty Ltd
20th Aug 20122:44 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
10th Aug 201212:20 pmPRNHolding(s) in Company
6th Aug 201212:21 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
3rd Aug 20125:35 pmPRNTR-1: Notification of Major Interest in Shares
2nd Aug 201212:12 pmPRNTR-1: Notification of Major Interest in Shares
2nd Aug 20129:00 amPRNAdmission of shares and Board update
31st Jul 201211:26 amPRNNotice of EGM
31st Jul 20127:00 amPRNResults of Open Offer
30th Jul 20125:35 pmPRNHolding(s) in Company
27th Jul 201212:12 pmPRNTR-1: Notification of Major Interest in Shares
24th Jul 20124:35 pmRNSPrice Monitoring Extension
13th Jul 20122:48 pmPRNReplacement - Subscription and Open Offer
12th Jul 20127:00 amPRNSubscription and Open Offer to Raise up to £5.7 million
10th Jul 201210:34 amPRNResponse to press speculation
22nd Jun 20121:35 pmPRNResult of Annual General Meeting
6th Jun 201212:00 pmPRNPhase I data for Atu027 and Potential Fundraising
17th May 20127:00 amPRNNew data from Phase I trial with Atu027
14th May 20127:00 amPRNPublication of 2011 Annual Report and Notice of AGM
3rd May 20127:00 amPRNSilence Therapeutics’ Partner extends agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.